Guerbet : Résultat S1 2024 dans le haut des attentes - Guidance de croissance du CA relevée (marge inchangée) de 1%
>MOP S1 2024 : 7,2% (vs 2,4% au S1 2023) - L’EBITDA S1 ressort à 61 M€, le ROC, à 30 M€, et le RN à 10 M€.Le FCF reste négatif (-29 M€ vs -72 M€) et la dette nette ressort à 365 M€, soit un levier à 3,2x (vs 3,5x fin juin 2023).Dans son communiqué, Guerbet indique s’attendre à i/ une croissance de son CA supérieure à 9% à ptc vs>8% auparavant (ODDO BHF : +9,5%e), ii/ un taux de marge d’EBITDA retraité à un niveau supérieur à celui connu en 2021 (14,4% / (ODD...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.